Loading clinical trials...
Loading clinical trials...
The purpose of this study is to assess severity of illness in schizophrenia patients in routine clinical practice at the time of entry in the study and after the treatment with Seroquel XR for 8 weeks. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Research Site
Bauska, Latvia
Research SIte
Cēsis, Latvia
Research Site
Daugavpils, Latvia
Research Site
Dobele, Latvia
Research Site
Jelgava, Latvia
Research Site
Jēkabpils, Latvia
Research Site
Jūrmala, Latvia
Research Site
Kuldīga, Latvia
Research Site
Liepāja, Latvia
Research Site
Riga, Latvia
Start Date
September 1, 2008
Primary Completion Date
March 1, 2009
Completion Date
March 1, 2009
Last Updated
December 10, 2010
80
ESTIMATED participants
Lead Sponsor
AstraZeneca
NCT07455929
NCT06740383
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions